Cypress Capital Group’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-3,455
| Closed | -$387K | – | 343 |
|
|
2021
Q4 | $387K | Sell |
3,455
-9,078
| -72% | -$1.02M | 0.05% | 232 |
|
|
2021
Q3 | $1.58M | Sell |
12,533
-681
| -5% | -$85.6K | 0.21% | 105 |
|
|
2021
Q2 | $1.79M | Buy |
13,214
+1,319
| +11% | +$179K | 0.24% | 97 |
|
|
2021
Q1 | $1.61M | Buy |
11,895
+4,682
| +65% | +$635K | 0.23% | 102 |
|
|
2020
Q4 | $1.02M | Buy |
7,213
+4,293
| +147% | +$604K | 0.15% | 120 |
|
|
2020
Q3 | $325K | Buy |
+2,920
| New | +$325K | 0.05% | 212 |
|
|
2019
Q2 | – | Sell |
-2,339
| Closed | -$212K | – | 247 |
|
|
2019
Q1 | $212K | Sell |
2,339
-500
| -18% | -$45.3K | 0.04% | 230 |
|
|
2018
Q4 | $204K | Sell |
2,839
-7,057
| -71% | -$507K | 0.05% | 227 |
|
|
2018
Q3 | $949K | Buy |
9,896
+1,504
| +18% | +$144K | 0.18% | 114 |
|
|
2018
Q2 | $799K | Buy |
+8,392
| New | +$799K | 0.16% | 120 |
|